Business Context and Reporting Period
Company: Inhibrx Biosciences, Inc. (INBX)
Filing Type: Form 8-K (Current Report)
Date of Report: December 16, 2025
Reporting Period: Event-based update regarding clinical trial progress for therapeutic candidates INBRX-106 and ozekibart (INBRX-109).
Key Financial Metrics
This filing is a Current Report on Form 8-K focused on clinical development updates and does not contain financial statements. Consequently, the filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes and Clinical Progress
INBRX-106 (Head and Neck Squamous Cell Carcinoma & NSCLC)
- HNSCC Phase 2/3 Trial: Recruited 46 of 60 patients in the randomized Phase 2 portion. Enrollment expected to complete in Q1 2026. Primary endpoint is overall response rate.
- NSCLC Phase 1/2 Trial: Completed enrollment of 34 patients in November 2025 for checkpoint inhibitor refractory or relapsed cases.
- Data Maturity: Current datasets for both indications lack sufficient maturity for interpretation. Data expected to be mature in H2 2026 to assess efficacy versus standard of care.
Ozekibart (INBRX-109) (Colorectal Cancer & Ewing Sarcoma)
- Colorectal Cancer: Completed enrollment of 44 patients in late October 2025 for the expansion cohort (combination with FOLFIRI). Progression-free survival data expected to mature in Q2 2026.
- Ewing Sarcoma: Enrollment for the combination trial (irinotecan and temozolomide) expected to complete in Q2 2026. FDA meeting to discuss accelerated approval pathway planned for H2 2026 if trends continue.
Guidance, Outlook, and Risks
Outlook: Management anticipates data maturity for INBRX-106 in H2 2026 and for ozekibart colorectal cancer in Q2 2026. An FDA meeting regarding accelerated approval for Ewing sarcoma is targeted for H2 2026.
Risks and Contingencies:
- Interim or topline data may not reflect final results or be predictive of future trials.
- Regulatory approval pathways, including accelerated approval, are not guaranteed.
- Orphan drug exclusivity may not effectively protect against competition.
- Unexpected adverse side effects or inadequate efficacy could limit development.
Investor Verification Checklist
- Verify the actual enrollment completion dates for the INBRX-106 HNSCC Phase 2 portion (targeted Q1 2026).
- Monitor the Q2 2026 data readout for ozekibart in colorectal cancer to confirm progression-free survival trends.
- Confirm the scheduling and outcome of the anticipated FDA meeting for Ewing sarcoma in H2 2026.
- Review the company's most recent Form 10-Q or 10-K for current cash runway and burn rate, as this 8-K contains no financial data.